Elisabetta Todisco

Varese, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 54 publications

Site-specific biology of tongue base aggressive B-cell lymphomas revealed by molecular subtype classification.

Site-specific biology of tongue base aggressive B-cell lymphomas revealed by molecular subtype classification.

Journal: Haematologica

Published: March 16, 2026

Correction: Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia.

Correction: Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia.

Journal: Blood cancer journal

Published: December 04, 2025

Late-onset progressive multifocal leukoencephalopathy after teclistamab in multiple myeloma: extending the timeline of infectious risk.

Late-onset progressive multifocal leukoencephalopathy after teclistamab in multiple myeloma: extending the timeline of infectious risk.

Journal: Haematologica

Published: December 03, 2025

NPM1 and IDH1/2 Mutations Show Limited Prognostic Impact in Relapsed/Refractory AML: Evidence From the AVALON Cohort.

NPM1 and IDH1/2 Mutations Show Limited Prognostic Impact in Relapsed/Refractory AML: Evidence From the AVALON Cohort.

Journal: Hematological oncology

Published: November 10, 2025

Venetoclax plus hypomethylating agents as effective bridge therapy to allogeneic stem cell transplant in relapsed/refractory acute myeloid leukaemia: A subanalysis of the AVALON study.

Venetoclax plus hypomethylating agents as effective bridge therapy to allogeneic stem cell transplant in relapsed/refractory acute myeloid leukaemia: A subanalysis of the AVALON study.

Journal: British journal of haematology

Published: July 29, 2025

Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia.

Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia.

Journal: Blood cancer journal

Published: July 29, 2025

Real-life management of 476 older adults with Philadelphia-negative acute lymphoblastic leukemia: a Campus ALL study.

Real-life management of 476 older adults with Philadelphia-negative acute lymphoblastic leukemia: a Campus ALL study.

Journal: Haematologica

Published: June 25, 2025

Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351.

Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351.

Journal: Blood advances

Published: May 19, 2025

Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351.

Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351.

Journal: Blood advances

Published: May 19, 2025

Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351.

Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351.

Journal: Blood advances

Published: May 19, 2025

Gilteritinib in FLT3-mutated acute myeloid leukemia: A real-world Italian experience.

Gilteritinib in FLT3-mutated acute myeloid leukemia: A real-world Italian experience.

Journal: Cancer

Published: May 06, 2025

Real World Study on the Best CPX-351 Treatment Duration and Timing for Allogeneic Stem Cell Transplantation.

Real World Study on the Best CPX-351 Treatment Duration and Timing for Allogeneic Stem Cell Transplantation.

Journal: American journal of hematology

Published: March 28, 2025

Showing 1-12 of 54

Last Updated: 09/26/2026